In Brief: Bayer bonds, Nestle investment, P&G and Abbott earnings, NAD reviews
This article was originally published in The Tan Sheet
Executive Summary
Bayer targets acquisitions with bond proceeds; Nestle commits $1 bil. to Mexico expansion; P&G health care sales grow 4%; U.S. sales slow Abbott Nutrition; NAD refers Grey Defence to FTC; Rainbow Light pulls anti-aging claims; and medical food warning letter.
You may also be interested in...
Major OTC Acquisitions, Expansion Likely In 2014
With major consumer product divisions potentially in play, analysts take a look at possible buyers and sellers in the OTC space. Switches and consumer business expansion plans are also likely to shape 2014.
Biogen/Ionis’ Tofersen: US FDA Considering Both Accelerated And Regular Approval In ALS
FDA seeks advisory committee input on whether there is ‘convincing evidence’ to support regular approval for treatment of SOD1-ALS patients even though lone Phase III trial failed its primary endpoint; companies filed for accelerated approval on the basis that a reduction in plasma neurofilament light chain is reasonably likely to predict clinical benefit.
Takeda’s High-Dose TYK2 Data Could Set It Apart In Psoriasis
Safety and efficacy data show that as long as Takeda can execute effectively on a Phase III program for TAK-279, the company should be well positioned in the oral psoriasis market.